Germany · Delayed Price · Currency is EUR Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of EUR 144.36 million. The enterprise value is 144.44 million.
| Market Cap | 144.36M |
| Enterprise Value | 144.44M |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 258.57M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +58.45% |
| Shares Change (QoQ) | +7.65% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 16.61% |
| Float | 229.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.55 |
| PB Ratio | 244.12 |
| P/TBV Ratio | 244.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.96 |
| EV / Sales | 25.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.00 |
Financial Position
The company has a current ratio of 3.42, with a Debt / Equity ratio of 22.75.
| Current Ratio | 3.42 |
| Quick Ratio | 3.27 |
| Debt / Equity | 22.75 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.65 |
| Interest Coverage | -7.60 |
Financial Efficiency
Return on equity (ROE) is -376.73% and return on invested capital (ROIC) is -75.21%.
| Return on Equity (ROE) | -376.73% |
| Return on Assets (ROA) | -57.86% |
| Return on Invested Capital (ROIC) | -75.21% |
| Return on Capital Employed (ROCE) | -158.10% |
| Revenue Per Employee | 75,333 |
| Profits Per Employee | -323,017 |
| Employee Count | 80 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0.20 |
Taxes
In the past 12 months, Oncopeptides AB has paid 92,441 in taxes.
| Income Tax | 92,441 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +266.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +266.57% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 0.30 |
| Relative Strength Index (RSI) | 59.77 |
| Average Volume (20 Days) | 1,184 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of EUR 5.65 million and -24.23 million in losses. Loss per share was -0.11.
| Revenue | 5.65M |
| Gross Profit | 5.53M |
| Operating Income | -22.21M |
| Pretax Income | -24.13M |
| Net Income | -24.23M |
| EBITDA | -21.98M |
| EBIT | -22.21M |
| Loss Per Share | -0.11 |
Balance Sheet
The company has 13.38 million in cash and 13.46 million in debt, giving a net cash position of -76,974.
| Cash & Cash Equivalents | 13.38M |
| Total Debt | 13.46M |
| Net Cash | -76,974 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 591,367 |
| Book Value Per Share | 0.00 |
| Working Capital | 12.25M |
Cash Flow
In the last 12 months, operating cash flow was -20.62 million and capital expenditures -32,291, giving a free cash flow of -20.65 million.
| Operating Cash Flow | -20.62M |
| Capital Expenditures | -32,291 |
| Free Cash Flow | -20.65M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 97.88% |
| Operating Margin | -393.09% |
| Pretax Margin | -427.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.45% |
| Shareholder Yield | -58.45% |
| Earnings Yield | -16.78% |
| FCF Yield | -14.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |